C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

Patents for C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
10/2002
10/30/2002	EP1253149A1 Sulfate salt of quinolonecarboxylic acid derivative and use thereof
10/30/2002	EP1252154A1 Heterocyclic amide derivatives
10/30/2002	EP1252146A1 Amide compounds for inhibiting protein kinases
10/30/2002	EP0854863B1 Esters and amides as pla2 inhibitors
10/30/2002	CN1377356A Certain alkylene diamine-substituted heterocycles
10/30/2002	CN1377336A Carboxylic acid derivatives and drugs containing the same
10/29/2002	US6472562 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
10/29/2002	US6472408 Two 5- amino-5,6,7,8-tetrahydroquinoline fragments joined together by a divalent linking group; cholinesterase inhibitors
10/29/2002	US6472407 α and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
10/29/2002	US6472391 Nitrogen-containing heterocyclic compounds
10/24/2002	WO2002083664A1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083663A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083645A1 Novel compounds
10/24/2002	WO2002083644A1 Halogenated quinoline derivatives and ectoparasite controllers
10/24/2002	WO2002083643A1 Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
10/24/2002	WO2002030931A3 Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
10/24/2002	WO2002002714A3 Electroluminescent iridium compounds with fluorinated phenylpyridines, phenylpyrimidines, and phenylquinolines and devices made with such compounds
10/24/2002	WO2002002516A3 Inhibitors of hiv integrase
10/24/2002	US20020156281 Anticholesterol agents; cardiovascular disorders; antilipemic agents; restenosis; dietetics
10/24/2002	US20020156097 Pharmaceuticals
10/24/2002	US20020156096 Two 5- amino-5,6,7,8-tetrahydroquinoline fragments joined together by a divalent linking group; cholinesterase inhibitors
10/24/2002	US20020156095 Treatment of depression, anxiety, psychosis, obesity, pain, Parkinson's disease, Alzheimer's disease, neurodegenerative diseases, movement disorders, respiratory diseases, inflammatory diseases, neuropathy, immune disorders, etc.
10/24/2002	US20020156089 Use of CRF antagonists and related compositions
10/24/2002	US20020156054 Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
10/24/2002	US20020156050 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors
10/24/2002	CA2443699A1 Phenyl heterocyclyl ether
10/23/2002	EP1251125A2 New camptothecin analogues, preparation methods thereof, use thereof as drugs, and pharmaceutical compositions containing them
10/23/2002	EP1251124A1 Process for the preparation of quinolylpropenal
10/23/2002	EP1251123A1 Process for preparing quinolylacrylonitrile and intermediates therefor
10/23/2002	EP1250324A1 Biaryl compounds, their preparation and their use in therapy
10/23/2002	CN1092960C Pharmaceutical composition comprising proteinase inhibitor and monoglyceride
10/22/2002	US6469056 Pharmaceutically active compounds, their preparation and use as ECE-inhibitors
10/22/2002	US6469047 Tyrosine derivatives
10/22/2002	US6469028 Synthesis and use of retinoid compounds having negative hormone and/or anatgonist activities
10/22/2002	US6469027 N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
10/17/2002	WO2002081728A2 Quinoline inhibitors of hyak1 and hyak3 kinases
10/17/2002	WO2002081451A1 Method for preparing 7-quinolinyl-3,5-dihydroxyhept-6-enoate
10/17/2002	WO2002050081A3 Antimicrobial agents
10/17/2002	US20020151566 Phosphodiesterase 4 inhibitors
10/16/2002	EP1249233A1 Npyy5 antagonists
10/16/2002	EP1248777A2 Tricyclic compounds with antiviral activity
10/16/2002	EP1248612A1 Novel compounds and compositions as protease inhibitors
10/16/2002	EP0831826B1 Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
10/16/2002	EP0538477B1 Novel cyclic aminophenylacetic acid derivative, production thereof, and immune response modulator containing the same as active ingredient
10/16/2002	CN1374863A Bicyclic antagonists selective for the alpha beta integrin
10/16/2002	CN1092642C Quinoline derivatives as tachykinin NK 3 receptor antagonists
10/15/2002	US6465654 Antiviral agents, that induce biosynthesis of interferon, and inhibit tumor formation
10/15/2002	US6465653 Heating and hydrolyzing/decarboxylating 4-hydroxyquinoline carboxylic acid ester in presence of water in liquid or vapor phase; plant safening agents
10/15/2002	US6465494 Methods for treatment of cystic fibrosis
10/15/2002	US6465468 Hydroxamic and carboxylic acid derivatives
10/15/2002	US6465433 Boronic ester and acid compounds, synthesis and uses
10/10/2002	WO2002079165A1 Tetrahydroquinoline derivatives as stat6-modulators, preparation and use thereof
10/10/2002	WO2002079164A1 Quinoline derivatives and their use as antibiotics
10/10/2002	WO2002079143A1 N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
10/10/2002	WO2002078626A2 Therapeutic combinations for cardiovascular and inflammatory indications
10/10/2002	WO2002078625A2 Therapeutic combinations for cardiovascular and inflammatory indications
10/10/2002	WO2002062763A3 Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas
10/10/2002	WO2002057215A3 Sodium channel modulators
10/10/2002	WO2002043667A3 HYDROLYSIS OF [R(R,R)]-2-(4-FLUOROPHENYL)-β,δ -DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
10/10/2002	WO2001072685A9 Polyamine analogues as cytotoxic agents
10/10/2002	US20020147342 Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
10/10/2002	US20020147192 Viricides; antiinflammatory agents; antiallergens; antiarthritic agents
10/10/2002	CA2442328A1 Therapeutic combinations for cardiovascular and inflammatory indications
10/10/2002	CA2437113A1 N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
10/09/2002	WO2001079168A1 Nitrogenous compounds and antiviral drugs containing the same
10/09/2002	EP1246817A1 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives
10/09/2002	EP1246804A1 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor
10/09/2002	EP1246803A1 Piperidine and piperazine derivatives which function as 5-ht 2a? receptor antagonists
10/09/2002	EP1246795A2 Antibacterial agents
10/09/2002	EP1246625A2 Methods and compositions for mitigating pain using nitrate esters
10/09/2002	EP1133495B1 Semi-hydrochloride of 8-cyan-1- cyclopropyl -7-(1s,6s-2 ,8-diazabicyclo 4.3.0]nonan -8-yl)-6- fluoro-1, 4-dihydro -4-oxo-3- quinoline carboxylic acid
10/09/2002	CN1373751A 'Alpha'-amino-'beta'-sulfonyl hydroxamic acid compounds
10/09/2002	CN1092181C Benzyloxy substd, aromatics and their use as fungicides and insecticides
10/09/2002	CA2405690A1 Nitrogen-containing compounds and antiviral drugs containing the same
10/08/2002	US6462073 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
10/08/2002	US6462055 Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group
10/08/2002	US6462048 3-(2-(4-methylpiperazin-1-yl)-benzylidene)-1,3-dihydro-indol-2-one for example; useful as psychotherapeutic agents
10/08/2002	US6462044 Therapy for sexual disorders
10/08/2002	CA2095361C Optical isomers of 7-¬3-(1,1-dialkylmethyl-1-amino)-1-pyrrolidinyl\|-quinolones and naphthyridones as antibacterial agents
10/03/2002	WO2002077609A2 Identification of compounds for the treatment or prevention of proliferative diseases
10/03/2002	WO2002076964A1 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same
10/03/2002	WO2002076939A2 Cysteine protease inhibitors
10/03/2002	WO2002076925A2 Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
10/03/2002	WO2002076395A2 Agents and methods for treatment of cancer
10/03/2002	WO2001085095A3 Chiral fluoroquinolizinone arginine salt forms
10/03/2002	WO2000034265A3 Quinoline-indole antimicrobial agents
10/03/2002	US20020143177 For inhibiting beta-secretase enzyme activity and A beta peptide production, inhibition of beta-secretase enzyme activity halts or reduces production of A beta from APP and reduces or eliminates the formation of beta-amyloid deposits
10/03/2002	US20020143034 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
10/03/2002	US20020143032 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
10/03/2002	CA2441394A1 Agents and methods for treatment of cancer
10/03/2002	CA2441080A1 Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
10/02/2002	EP1245566A1 Quinolin-4-one derivatives and their use as antibiotics
10/02/2002	EP1244650A1 Arylamine derivatives and their use as anti-telomerase agent
10/02/2002	EP1244630A1 Amphiphilic polyamines, the use and method for synthesis thereof
10/02/2002	EP1244629A2 Quinolone compounds for use in treating viral infections
10/02/2002	EP1244628A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
10/02/2002	EP1244626A2 Caspase inhibitors and uses thereof
10/02/2002	CN1371904A Improved method for preparing fluoro-quinolone carboxylic acid
10/01/2002	US6458800 1,2-annelated quinoline derivatives
10/01/2002	US6458779 Treatment of conditions associated with excess production of soluble cd23 (s-cd23) such as autoimmune disease and allergy. the compounds of the invention are also inhibitors of the release of tumour necrosis factor (tnf).

1 ... 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 ... 277